Fouad Namouni M.D.
Net Worth
Last updated:
What is Fouad Namouni M.D. net worth?
The estimated net worth of Dr. Fouad Namouni M.D. is at least $13,190,721 as of 3 Oct 2024. He owns shares worth $8,941,802 as insider, has earned $1,602,599 from insider trading and has received compensation worth at least $2,646,320 in Blueprint Medicines Corporation.
What is the salary of Fouad Namouni M.D.?
Dr. Fouad Namouni M.D. salary is $661,580 per year as Pres of R&D in Blueprint Medicines Corporation.
How old is Fouad Namouni M.D.?
Dr. Fouad Namouni M.D. is 56 years old, born in 1969.
What stocks does Fouad Namouni M.D. currently own?
As insider, Dr. Fouad Namouni M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Blueprint Medicines Corporation (BPMC) | Pres of R&D | 69,070 | $129.46 | $8,941,802 |
What does Blueprint Medicines Corporation do?
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Fouad Namouni M.D. insider trading
Blueprint Medicines Corporation
Dr. Fouad Namouni M.D. has made 8 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,633 units of BPMC stock worth $324,500 on 3 Oct 2024.
The largest trade he's ever made was exercising 4,377 units of BPMC stock on 7 Mar 2024. As of 3 Oct 2024 he still owns at least 69,070 units of BPMC stock.
Blueprint Medicines key executives
Blueprint Medicines Corporation executives and other stock owners filed with the SEC:
- Dr. Fouad Namouni M.D. (56) Pres of R&D
- Mr. Alexis A. Borisy A.M. (53) Co-Founder & Director
- Mr. Jeffrey W. Albers J.D., M.B.A., MBA (54) Chairman, Chief Executive Officer & Pres
- Mr. Michael Landsittel (53) Chief Financial Officer & Treasurer
- Ms. Kathryn Haviland (49) Chief Operating Officer
- Ms. Tracey L. McCain Esq. (57) Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec.